AKRO
NASDAQ
US
Akero Therapeutics, Inc. - Common Stock
$54.65
+0.16 (+0.3%)
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.5B
ROE
-30.7%
D/E
0.00
Beta
-0.40
52W
$21–$58
Wall Street Consensus
16 analysts · Apr 20262
Strong Buy
6
Buy
8
Hold
0
Sell
0
Strong Sell
50.0%
Buy Rating
Price Chart
Similar Stocks
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
DNLI
Denali Therapeutics Inc
$2.6B
About Akero Therapeutics, Inc. - Common Stock
AKRO - біотехнологічна компанія, що спеціалізується на розробці та комерціалізації таргетної терапії раку. Вони використовують інноваційні підходи для створення ліків, які більш ефективно знищують ракові клітини, мінімізуючи побічні ефекти. AKRO має перспективну позицію на ринку, завдяки своїм унікальним технологіям та клінічним дослідженням.
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-1.00
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.00 | — | — |
| Sep 2025 | $-0.94 | $-0.98 | $-0.04 |
| Jun 2025 | $-0.93 | $-0.86 | +$0.07 |
| Mar 2025 | $-0.99 | $-0.90 | +$0.09 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -31.6% | -31.6% | -31.6% | -31.6% | -30.7% | -30.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 3.48 | 3.48 | 3.48 | 3.48 | 0.00 | 0.00 |
| Current Ratio | 12.66 | 12.66 | 12.66 | 12.66 | 15.83 | 15.83 |
Key Ratios
ROA (TTM)
-28.6%
P/B
2.6
EPS (TTM)
$-3.75
CF/Share
$-2.38
52W High
$58.40
52W Low
$21.34
$21.34
52-Week Range
$58.40
How does AKRO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AKRO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.6
▲
5%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AKRO profitability vs Biotechnology peers
ROE
-30.7%
▲
54%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-28.6%
▲
39%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
AKRO financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
15.8
▲
257%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.4
▼
142%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
AKRO fundamentals radar
AKRO
Peer median
Industry
AKRO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AKRO vs peers: key metrics
Latest News
No related news yet